Adaptive Biotechnologies Corp (ADPT)vsIQVIA Holdings Inc (IQV)
ADPT
Adaptive Biotechnologies Corp
$24.20
-0.12%
HEALTHCARE · Cap: $3.90B
IQV
IQVIA Holdings Inc
$261.77
+1.74%
HEALTHCARE · Cap: $42.24B
Smart Verdict
WallStSmart Research — data-driven comparison
IQVIA Holdings Inc generates 5413% more annual revenue ($16.98B vs $308.08M). IQV leads profitability with a 8.1% profit margin vs -20.7%. IQV earns a higher WallStSmart Score of 55/100 (C).
ADPT
Avoid28
out of 100
Grade: F
IQV
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+51.0%
Fair Value
$31.91
Current Price
$24.20
$7.71 discount
Margin of Safety
+11.9%
Fair Value
$201.21
Current Price
$261.77
$60.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 21.5% year-over-year
Every $100 of equity generates 22 in profit
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Trading at 26.9x book value
ROE of -23.0% — below average capital efficiency
Negative free cash flow — burning cash
Premium valuation, high expectations priced in
Weak financial health signals
Earnings declined 0.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : ADPT
The strongest argument for ADPT centers on Revenue Growth. Revenue growth of 21.5% demonstrates continued momentum.
Bull Case : IQV
The strongest argument for IQV centers on Return on Equity, PEG Ratio. PEG of 0.97 suggests the stock is reasonably priced for its growth.
Bear Case : ADPT
The primary concerns for ADPT are EPS Growth, Price/Book, Return on Equity. Debt-to-equity of 2.87 is elevated, increasing financial risk.
Bear Case : IQV
The primary concerns for IQV are P/E Ratio, Piotroski F-Score, EPS Growth. Debt-to-equity of 2.63 is elevated, increasing financial risk.
Key Dynamics to Monitor
ADPT profiles as a growth stock while IQV is a value play — different risk/reward profiles.
ADPT carries more volatility with a beta of 2.10 — expect wider price swings.
ADPT is growing revenue faster at 21.5% — sustainability is the question.
IQV generates stronger free cash flow (360M), providing more financial flexibility.
Bottom Line
IQV scores higher overall (55/100 vs 28/100). ADPT offers better value entry with a 51.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Adaptive Biotechnologies Corp
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
Visit Website →IQVIA Holdings Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?